Advertisement
Singapore markets open in 1 hour 19 minutes

  • Straits Times Index

    3,187.66
    +32.97 (+1.05%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • Dow

    37,775.38
    +22.07 (+0.06%)
     

  • Nasdaq

    15,601.50
    -81.87 (-0.52%)
     

  • Bitcoin USD

    63,484.91
    +2,178.59 (+3.55%)
     

  • CMC Crypto 200

    1,313.09
    +427.55 (+48.28%)
     

  • FTSE 100

    7,877.05
    +29.06 (+0.37%)
     

  • Gold

    2,395.40
    -2.60 (-0.11%)
     

  • Crude Oil

    82.56
    -0.17 (-0.21%)
     

  • 10-Yr Bond

    4.6470
    +0.0620 (+1.35%)
     

  • Nikkei

    38,079.70
    +117.90 (+0.31%)
     

  • Hang Seng

    16,385.87
    +134.03 (+0.82%)
     

  • FTSE Bursa Malaysia

    1,544.76
    +4.34 (+0.28%)
     

  • Jakarta Composite Index

    7,166.81
    -7,130.84 (-49.87%)
     

  • PSE Index

    6,523.19
    +73.15 (+1.13%)
     

CTMX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 20, 2020 in the Class Action Filed on Behalf of CytomX Therapeutics, Inc. Limited Shareholders

Newsfile Corp.
·1-min read

New York, New York--(Newsfile Corp. - June 1, 2020) -  The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of CytomX Therapeutics, Inc. (NASDAQ: CTMX) alleging that the Company violated federal securities laws.

Class Period: May 17, 2018 and May 13, 2020
Lead Plaintiff Deadline: July 20, 2020

Learn more about your recoverable losses in DNK:
http://www.kleinstocklaw.com/pslra-1/cytomx-therapeutics-inc-loss-submission-form?id=7057&from=5

The filed complaint alleges that CytomX Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) CytomX had downplayed issues with CX-072's efficacy observed in the PROCLAIM-CX-072 clinical program; (ii) CytomX had similarly downplayed issues with CX-2009's efficacy and safety observed in the PROCLAIM-CX-2009 clinical program; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

ADVERTISEMENT

Shareholders have until July 20, 2020 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

For additional information about the CTMX lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click the link above.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/57033